Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study
Authors' conclusion
Among adults with T2D, MASLD was associated with substantially higher healthcare costs and utilisation.
Study context
- Population
- Adults aged 18–64 years with T2D, IQVIA PharMetrics Plus Closed Health Plan data, January 2016 to June 2025, United States
- Participants
- 155,172 adults17,412 matched pairs
- Exposure
- T2D with diagnosed MASLD vs T2D-only controls
- Outcome
- All-cause total direct healthcare costs
- Follow-up
- 12 months
Methodological detailspropensity-score matched 1:1
- Propensity-score matched 1:1
Main finding
As reported in the abstract
Total healthcare costs · 12 months
aCR
1.62
95% CI 1.58–1.67
62% higher total healthcare costs
AME
$11 411 per patient per year (95% CI $10 725-$12 097)
Total healthcare costs
MASLD
$29 734
mean
Matched controls
$18 320
mean
Observational data: associations, not effects.
Further findings
| Outcome | AME |
|---|---|
| Excess costs in GLP-1 RA subgroup | $10 653 |
| Excess costs in SGLT2i subgroup | $13 842 |
Healthcare utilisation
- MASLD associated with greater healthcare utilisation across all service settings
Original publication
Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study. Diabetes Obes Metab. Published 14 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →